

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

RELTON *et al.*

Application No.: 10/587,714

371(c) Date: June 4, 2007

For: **Treatment of Conditions Involving  
Dopaminergic Neuronal Degeneration Using  
Nogo Receptor Antagonists**

Confirmation No.: 2306

Art Unit: 1646

Examiner: Sandra L. WEGERT

Atty. Docket: 2681.0450001/EJH/JBF

**Statement of Substance of Interview  
In Accordance With 37 C.F.R. § 1.133(b) and M.P.E.P. § 713.04**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

*Mail Stop Amendment*

Sir:

In reply to the Interview Summary (Form PTOL-413) mailed by the U.S. Patent & Trademark Office (USPTO) on January 4, 2012, Applicants submit herewith the following Statement of Substance of the Interview held with Examiner Sandra Wegert on December 2, 2011, regarding the above captioned application in accordance with 37 C.F.R. § 1.133(b) and M.P.E.P. § 713.04.

A summary of the interview follows:

Applicants thank the Examiner for her time in participating in a telephone interview on December 2, 2011, with Applicants' representative Jeremiah Frueauf. In the interview, Applicants' representative indicated that the Office Action of June 14, 2011, did not appear to address the Declaration under 37 C.F.R. § 1.132 submitted with Applicants' Amendment and Reply under 37 C.F.R. § 1.114 filed on August 16, 2010. The Examiner agreed to consider the Declaration and indicated that the USPTO would issue a new Office Action to consider the Declaration and withdraw the Office Action of June 14, 2011.

The Examiner is invited to contact Applicants' undersigned representative at the number provided with any inquiries regarding this Statement.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read 'Jeremiah B. Frueauf', written over a dotted line.

Jeremiah B. Frueauf  
Attorney for Applicants  
Registration No. 66,638

Date: February 1, 2012

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600